ERBB2 and ductal breast carcinoma in situ: The systematic use of HER2 IHC in the histopathological work-up of DCIS could therefore improve the reproducibility of grading, which is an important prognostic factor to identify those patients at risk of developing a second ipsilateral breast tumor, either in situ or invasive.